Research
Energy balance
Cagrilintide, a stable amylin analogue, is under clinical development for obesity treatment.
Cagrilintide may offer a new approach to obesity management.
StrongSupportsmedium confidence
Given that the stable amylin analogue cagrilintide is under clinical development for the treatment of obesity.
Why this rating
The claim is based on ongoing clinical development.
Source
Central nervous system pathways targeted by amylin in the regulation of food intake
Mohammed K. Hankir et al. · Biochimie · 2024
DOI 10.1016/j.biochi.2024.10.012
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →